Alto Neuroscience (ANRO) Net Cash Flow (2023 - 2026)

Alto Neuroscience has disclosed Net Cash Flow across 4 years of filings, most recently posting $87.3 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $87.3 million, up 1271.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $103.0 million (up 330.95% YoY), and the FY2025 annual result was $8.3 million, down 90.39% from the prior year.
• Net Cash Flow came in at $87.3 million for Q1 2026 at Alto Neuroscience, up from $38.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $123.4 million in Q1 2024 to a low of -$13.5 million in Q4 2024.
• The 4-year median for Net Cash Flow is -$7.5 million (2025), against an average of $16.6 million.
• Across the five-year window, Net Cash Flow tumbled 143.12% in 2024 and jumped 1271.26% in 2026, its largest moves.
• Alto Neuroscience's Net Cash Flow stood at $31.3 million in 2023, then sank by 143.12% to -$13.5 million in 2024, then surged by 386.9% to $38.7 million in 2025, then surged by 125.75% to $87.3 million in 2026.
• The last three Net Cash Flow figures came in at $87.3 million (Q1 2026), $38.7 million (Q4 2025), and -$9.8 million (Q3 2025), per Business Quant data.